Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases

• US 20080214437A1
• Filed: 11/30/2007
• Published: 09/04/2008
• Est. Priority Date: 09/06/2002
• Status: Abandoned Application

• Current Assignee: Shyam S. Mohapatra, Subhra Mohapatra, Weidong Xu, XIaoqin Wang, Xiaoyuan Kong
• Original Assignee: Shyam S. Mohapatra, Subhra Mohapatra, Weidong Xu, XIaoqin Wang, Xiaoyuan Kong
• Inventors: Mohapatra, Shyam S., Xu, Weidong, Kong, Xiaoyuan, Wang, Xiaoqin, Mohapatra, Subhra
• Application Number:
  US11/998,792
• Publication Number:
  US 20080214437A1
• Time in Patent Office: Days
• US Class Current: 514/2
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61K 47/6935 the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
• CPC Class Codes: A61K 47/6939 the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61K 49/0008 Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0043 Nose
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/5161 Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/111 : spanning the whole gene, or a large part of it
• CPC Class Codes: C12N 2310/14 : interfering N.A.
• CPC Class Codes: C12N 2320/30 : Special therapeutic applications

Abstract

Methods, compositions and devices are provided by the present invention for reducing activity of a natriuretic peptide receptor and other signals. Therapeutic treatments are provided by use of polynucleotides encoding a natriuretic peptide or by regulating the expression of natriuretic peptide receptor, such as NPRA and NPRC, or combinations of these therapies. Routes used for delivering polynucleotides encoding a natriuretic peptide, or, for example, siRNA that down regulates natriuretic peptide receptor include subcutaneous injection, oral gavage, transdermal and intranasal delivery routes. Compositions can include chitosan, chitosan derivatives, and chitosan derivative and a lipid. Transdermal delivery can use a transdermal cream. Intranasal delivery can use a dropper or an aspirator for delivery of a mist. Oral gavage delivers equivalent to oral delivery. Delivery permits cell and tissue specific targeting of gene therapies resulting in expression of a natriuretic peptide or down regulation of natriuretic peptide receptor. A variety of cancers, asthma and viral diseases can be treated therapeutically using the methods and compositions of the present invention.

Claims

1. A method for reducing activity of a natriuretic peptide receptor comprising:

selecting a polynucleotide wherein

the polynucleotide is a polynucleotide complementary with a portion of a natriuretic peptide receptor gene;

or

the polynucleotide is a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA;

or

the polynucleotide is a polynucleotide encoding the polynucleotide complementary with a portion of the natriuretic peptide receptor messenger RNA;

and administering the selected polynucleotide or a combination such that the selected polynucleotide or the combination reduces or inhibits expression of a natriuretic peptide receptor gene.

2. The method of claim 1, further comprising:

complexing the selected polynucleotide with a chitosan or a chitosan derivative, or complexing the selected polynucleotide with a combination of a lipid and the chitosan or a chitosan derivative.

3. The method of claim 2, wherein the step of complexing complexes the selected polynucleotide with the chitosan or a chitosan derivative.

4. The method of claim 1, wherein the portion of the natriuretic peptide receptor gene that is complementary with the selected polynucleotide complementary with the portion of the natriuretic peptide receptor gene includes a portion of a natriuretic peptide receptor A gene.

5. The method of claim 4, wherein the portion of the natriuretic peptide receptor A gene includes a human natriuretic peptide receptor A gene, or a portion thereof.

6. The method of claim 1, wherein the portion of the natriuretic peptide receptor gene includes a portion of a natriuretic peptide receptor C gene.

7. The method of claim 1, wherein the step of selecting selects a polynucleotide complementary with a portion of a natriuretic peptide receptor gene and wherein the polynucleotide comprises an antisense molecule.

8. The method of claim 1, wherein the step of selecting selects a polynucleotide complementary with a portion of a natriuretic peptide receptor gene and wherein the polynucleotide comprises a ribozyme.

9. The method of claim 1, wherein the step of selecting selects a polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA and wherein the polynucleotide comprises at least one siRNA.

10. The method of claim 9, wherein the polynucleotide is provided in a plasmid vector and the polynucleotide comprises a nucleotide sequence of SEQ ID No:

23, SEQ ID No;

24, or SEQ ID No;

25.

11. The method of claim 9, wherein the step of selecting selects a plurality of polynucleotides, wherein the plurality of polynucleotides comprises a nucleotide sequence of SEQ ID No:

23 and SEQ ID No;

24.

12. The method of claim 1, wherein the step of administering comprises a route selected from the group consisting of inhalation, intramuscular, intravenous, intranasal, oral or transdermal.

13. The method of claim 1, further comprising the step of complexing the selected polynucleotide with a chitosan or a chitosan derivative to form a complex, wherein the step of administering includes a protocol for treating a respiratory viral infection including a step of delivering the complex intranasally or by inhalation.

14. The method of claim 1, wherein the step of selecting includes use of a vector plasmid comprising a tissue specific promoter linked with a methionine initiated DNA sequence to form the selected polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA.

15. The method of claim 1, wherein the step of selecting selects a polynucleotide comprising a polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA, wherein the polynucleotide is a siRNA complementary with a natriuretic peptide receptor A messenger RNA, whereby expression of natriuretic peptide receptor A is reduced.

16. The method of claim 14, wherein the selected polynucleotide encodes an siRNA that comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:

23, SEQ ID NO;

24, and SEQ ID NO;

25.

60. The method according to claim 1, wherein the selected polynucleotide is provided as a complex with chitosan or a chitosan derivative and the complex is administered intranasally or by inhalation for the treatment of a respiratory viral infection.

63. The method of claim 1, wherein the step of selecting selects a polynucleotide that is complementary with a portion of a natriuretic peptide receptor messenger RNA and wherein the polynucleotide comprises at least one siRNA.

64. The method of claim 63, wherein the polynucleotide comprises the nucleotide sequence of SEQ ID NO:

21, or SEQ ID No;

22.

17. A method for treating an inflammatory disorder, a viral infection or a cell proliferation disorder treatable by inducing apoptosis, comprising:

selecting a polynucleotide, wherein the polynucleotide is a polynucleotide encoding a natriuretic hormone peptide operably linked to a tissue specific promoter, or the polynucleotide is a polynucleotide complementary with a portion of a natriuretic peptide receptor gene or the polynucleotide is complementary with a portion of a natriuretic peptide receptor messenger RNA or a polynucleotide encoding a natriuretic peptide receptor, or the polynucleotide includes a plurality of polynucleotides including a combination of any of the following polynucleotides where the combination includes a polynucleotide encoding a natriuretic hormone peptide and an operably linked promoter and a polynucleotide complementary with a portion of a natriuretic peptide receptor gene or a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA or a polynucleotide encoding a natriuretic peptide receptor; and

administering or delivering an effective amount of the selected polynucleotide to a person or animal in need of treatment.

18. The method of claim 17, comprising the step of selecting, wherein the portion of the natriuretic peptide receptor gene comprises a portion of a natriuretic peptide receptor A gene and the polynucleotide is selected from the group consisting of a siRNA, an antisense molecule, and a ribozyme.

19. The method of claim 18, wherein the siRNA comprises polynucleotide sequence selected from the group consisting of SEQ ID NO:

21 and SEQ ID NO;

22.

20. The method of claim 17, wherein the step of selecting includes selecting the polynucleotide encoding expression of a natriuretic hormone peptide, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO. 1, 2, 3, 4, 5 and 6.

21. The method of claim 20, wherein the polynucleotide encoding expression of a natriuretic hormone peptide encodes a peptide that comprises the amino acid sequence of SEQ ID NO:

5.

22. The method of claim 17, wherein the step of delivering delivers by a route selected from the group consisting of inhalation, intramuscular, intravenous, intranasal, oral, sublingual and transdermal.

23. The method of claim 22, wherein the step of delivering includes complexing the polynucleotide with a chitosan or a chitosan derivative to form a complex and dispersing the complex in a liquid.

24. The method of claim 23, wherein the steps of selecting selects a polynucleotide capable of therapeutically treating a cancer from the group consisting of breast cancer, lung cancer, ovarian cancer, prostrate cancer, and melanoma.

25. The method of claim 24, wherein the cancer is breast cancer and the step of delivering uses intranasal delivery.

26. The method of claim 24, wherein the cancer treated is lung cancer, and the step of delivering uses intranasal delivery.

27. The method of claim 24, wherein the cancer treated is ovarian cancer, and the step of delivering uses intravaginal delivery.

28. The method of claim 24, wherein the cancer treated is prostate cancer, and the step of delivering uses intranasal delivery.

29. The method of claim 24, wherein the cancer treated is a melanoma and the step of delivering uses transdermal delivery.

30. The method of claim 17, wherein the step of delivering includes inhaling the polynucleotide for treating respiratory syncytial viral infection.

31. The method of claim 17, wherein the step of delivering includes delivering the polynucleotide transdermally for treating asthma.

32. The method of claim 17, further comprising:

selecting an expression vector and combining the expression vector and the selected polynucleotide.

33. The method of claim 32, wherein the expression vector includes an expression vector selected from the group of expression vectors consisting of pVAX and a PU6 plasmid.

34. The method of claim 33, wherein the polynucleotide comprises a nucleotide sequence selected from SEQ ID NO:

21, SEQ ID NO;

22, SEQ ID NO;

23, SEQ ID NO;

24 or SEQ ID NO;

25, and the method further comprises complexing of the polynucleotide with chitosan or a chitosan derivative.

35. The method of claim 33, wherein the polynucleotide encodes expression of a natriuretic hormone peptide encodes a peptide comprising the amino acid sequence of SEQ ID NO:

5, such that a natriuretic hormone peptide comprising SEQ ID NO;

5 is expressed.

36. The method of claim 17, wherein the natriuretic peptide receptor gene comprises a portion of a natriuretic peptide receptor C gene and the step of selecting includes at least one polynucleotide complementary with the portion of natriuretic peptide receptor C gene.

37. The method of claim 36, wherein the step of selecting selects a plurality of polynucleotides, the plurality of polynucleotides including a polynucleotide complementary with a portion of a natriuretic peptide receptor A gene and a polynucleotide complementary with a portion of a natriuretic peptide receptor gene.

65. The method of claim 17, wherein the portion of the natriuretic peptide receptor messenger RNA is a portion of a natriuretic peptide receptor messenger RNA and the polynucleotide selected comprises a polynucleotide complementary with the portion of the natriuretic peptide receptor messenger RNA.

66. The method of claim 65, wherein the selected polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:

23, SEQ ID NO;

24, and SEQ ID NO;

25.

67. The method of claim 17, wherein the portion of the natriuretic peptide receptor messenger RNA is a portion of a natriuretic peptide receptor A messenger RNA and the polynucleotide selected comprises a polynucleotide complementary with the portion of the natriuretic peptide receptor A messenger RNA.

68. The method of claim 67, wherein the selected polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NO:

21 and SEQ ID NO;

22.

38. A polynucleotide comprising:

a polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor A messenger RNA, such that the polynucleotide complementary with a portion of a natriuretic peptide receptor A messenger RNA reduces or inhibits expression of a natriuretic peptide receptor A gene.

39. The polynucleotide of claim 38, wherein the polynucleotide comprises a nucleotide sequence selected from the group of polynucleotides consisting of SEQ ID NO:

23, SEQ ID NO;

24, and SEQ ID NO;

25.

40. A method for reducing activity of a natriuretic peptide receptor comprising:

selecting a polynucleotide means for reducing or inhibiting expression of a natriuretic peptide receptor;

providing a means for delivering the polynucleotide means to cells in vivo; and

administering the polynucleotide means using the means for delivering.

41. The method of claim 40, wherein the polynucleotide means includes a polynucleotide encoding an siRNA complementary with a natriuretic peptide receptor A messenger RNA;

and the means for delivering includes complexing the polynucleotide with chitosan or a chitosan derivative to form a complex, and administering the complex intramuscularly, subcutaneously, intranasally, transdermally, orally, or by inhalation.

42. The method of claim 41, wherein the means for delivering includes complexing the complex with a lipid.

43. The method of claim 42, wherein the lipid is a cationic lipid or a phospholipid.

44. A pharmaceutical composition comprising:

a polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA such that activity of a natriuretic peptide receptor gene is regulated when the polynucleotide is administered in vivo.

45. The pharmaceutical composition of claim 44, wherein the polynucleotide encodes a siRNA and comprises SEQ ID NO:

23.

46. The pharmaceutical composition of claim 45, further comprising the polynucleotide encoding the siRNA provided in a plasmid and a chitosan or a chitosan derivative for complexing with the plasmid.

47. The pharmaceutical composition of claim 44, wherein the polynucleotide encodes a siRNA and comprises SEQ ID NO:

24.

48. The pharmaceutical composition of claim 47, further comprising the polynucleotide encoding the siRNA provided in a plasmid and a chitosan or a chitosan derivative for complexing with the plasmid.

49. The pharmaceutical composition of claim 44 wherein the polynucleotide encodes a siRNA and comprises SEQ ID NO:

25.

50. The pharmaceutical composition of claim 49, further comprising the polynucleotide encoding the siRNA provided in a plasmid and a chitosan or a chitosan derivative for complexing with the plasmid.

51. The pharmaceutical composition of claim 44, further comprising a chitosan or a chitosan derivative, or a combination of the lipid and chitosan or a chitosan derivative.

52. The pharmaceutical composition of claim 50, wherein the ratio of chitosan or a chitosan derivative to the polynucleotide is a ratio in a range from 5:

1 to 1;

1 on a weight by weight basis.

53. A therapeutic device, comprising:

a polynucleotide encoding a peptide that comprises the amino acid sequence of SEQ ID No. 5;

a chitosan or chitosan derivative complexed with the polynucleotide to form a complex; and

a means for delivering the complex in vivo therapeutically.

54. The device of claim 53, wherein the means for delivering intranasally includes providing a means in a form of nasal drop or nasal spray, wherein the complex is dispersed in a liquid prior to delivery of the complex.

55. The device of claim 53, wherein the means for delivering includes an atomizer, whereby a mist containing the complex is delivered intranasally.

56. The device of claim 53, wherein the means for delivering includes an inhaler for delivery of the complex by inhalation.

57. The device of claim 53, wherein the means for delivering includes a nebulizer, whereby the complex is delivered to a deep part of the respiratory tract.

58. A method of therapeutically treating a disorder, comprising:

deactivating NFκ

B, or reducing or inhibiting expression or activity of NFκ

B, by administering an effective amount of a polynucleotide or polypeptide or agent that reduces or inhibits expression or activity of NFκ

B to a person or animal in need of treatment.

59. The method of claim 58, wherein the polynucleotide encodes an siRNA complementary with a portion of a NPRA messenger RNA;

combining the polynucleotide to form a polynucleotide effective in reducing the expression of the NPRA;

complexing the polynucleotide with a chitosan or a chitosan derivative to form a complex; and

administering the complex.

61. A method for reducing activity or expression of a natriuretic peptide receptor in a cell, the method comprising contacting or delivering to the cell an effective amount of a polynucleotide encoding a natriuretic peptide, or an effective amount of a polynucleotide having a nucleotide sequence that is complementary with a portion of a natriuretic peptide receptor gene, or an effective amount of a polynucleotide encoding a siRNA complementary with a portion of a natriuretic peptide receptor messenger RNA or complementary with a nucleic acid sequence encoding a natriuretic peptide receptor.

62. A method for reducing activity or expression of a natriuretic peptide receptor in a cell of a person or animal, said the method comprising administering to the person or animal an effective amount of a polynucleotide encoding a natriuretic peptide, or an effective amount of a polynucleotide having a nucleotide sequence that is complementary with a portion of a natriuretic peptide receptor gene or an effective amount of a polynucleotide encoding a polynucleotide complementary with a portion of a natriuretic peptide receptor messenger RNA or complementary with a nucleic acid sequence encoding a natriuretic peptide receptor.